Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The following transaction-specific prices are noted:
- Ordinary Share Price: 1742.50 pence
- American Depositary Share (ADS) Price: $52.91
Material Changes
The filing details increases in notional interests in Ordinary Shares and ADSs following the notional re-investment of the dividend paid to shareholders on July 11, 2013. Specific changes include:
- Dr M M Slaoui: Increase of 39.692 ADSs (Connected Person: Dr K Slaoui).
- Mr P C Thomson: Increase of 64.442 Ordinary Shares (Connected Person: Mrs K Thomson).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares held by Dr M M Slaoui and Mr P C Thomson post-transaction.
- Review the dividend payment details from July 11, 2013, to validate the basis for the notional re-investment.